ANDA 79014, held by PharmoBedient. Alfuzosin Hydrochloride.
As of Nov 22, 2026, ANDA 79014 (Alfuzosin Hydrochloride), held by PharmoBedient, was first approved by FDA on Jul 18, 2011, with 3 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 18, 2011 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Alfuzosin Hydrochloride10MG · tablet, extended release;oral | Alfuzosin Hydrochloride | Discontinued |
| Sep 23, 2022 | Supplement 9Labeling · Standard review | Approved | None posted |
| Nov 14, 2018 | Supplement 8Labeling · Standard review | Approved | None posted |
| Jan 13, 2015 | Supplement 6Labeling · Standard review | Approved | None posted |
| Jul 18, 2011 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters